Drug intelligence / Profile preview

doramectin

Development stage
Phase 3
Lead developer
Zoetis
Modality
Small Molecules
Administration
Intramuscular, Subcutaneous, Topical
01

Overview

Doramectin is a semisynthetic avermectin and macrocyclic lactone used as a veterinary antiparasitic drug. It is approved for the treatment and control of internal and external parasites—including gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice, mange mites, ticks, and other ectoparasites—in cattle and swine[1][2][4][5]. Doramectin acts primarily by binding to glutamate-gated chloride channel receptor in the nervous system of nematodes and arthropods. This increases membrane permeability to chloride ions leading to paralysis and death of the parasite[2][6]. It may also enhance GABA release at presynaptic neurons in parasites[6]. Doramectin is produced by fermentation from Streptomyces avermitilis followed by chemical modification[4][6]. It is available as injectable or topical formulations for animals. While not approved for human use or dairy cattle[5], research has explored its potential anticancer effects via autophagy induction through PI3K/AKT/mTOR pathway inhibition in glioblastoma models[8].

Brand names
DectomaxDectoGardValcor
Other names
DRM
02

Targets

GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on doramectin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on doramectin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call